Signature Therapeutics

Signature Therapeutics develops drugs that target large markets with unmet needs where the mechanism of action is well understood.

The current pipeline of drugs in development remediates problematic pain killer abuse by providing pain relief without addiction, including abuse-resistant opioids for moderate-to-severe pain, as well as compounds addressing the psychostimulant, sedative, and oncology markets.